@article{APS9918,
author = {Jing Zhou and Wen-li Li and Zi-xuan Wang and Nai-yuan Chen and Yue Tang and Xiao-xiao Hu and Jing-huan Deng and Yixin Lu and Guo-dong Lu},
title = {Varacin-1, a novel analog of varacin C, induces p53- independent apoptosis in cancer cells through ROS-mediated reduction of XIAP},
journal = {Acta Pharmacologica Sinica},
volume = {40},
number = {2},
year = {2019},
keywords = {},
abstract = {Varacin C is a promising anticancer agent and possesses acid-promoted and photo-induced DNA-damaging activities. In this study, we synthesized an analog varacin-1 (VCA-1) and examined its anticancer potentials. The results demonstrated that VCA-1 caused dose-dependent apoptotic cell death in cancer cells. Note that this action is independent of p53 status, because VCA-1 induced similar levels of apoptosis in two different panels of cell lines (HCT116 p53- wild-type vs. HCT116 p53-knockout colon cancer cells, and p53-expressing U2OS vs. p53-deficient saos2 osteosarcoma cancer cells). VCA-1-induced apoptosis was found to be mainly via the extrinsic apoptosis pathway involving caspase-8 activation and XIAP reduction. Forced over-expression of XIAP markedly prevented apoptosis, indicating its essential role in VCA-1 induced apoptosis. On the other hand, VCA-1 treatment enhanced intracellular ROS (reactive oxygen species) generation also in a p53-independent manner, and consequently promoted caspase activation. Pretreatment of N-acetyl cysteine (an antioxidant), rather than z-VAD (specific caspase inhibitor), markedly prevented XIAP reduction, suggesting that XIAP reduction may be resulted from oxidative stress. In conclusion, data from this study reveal the essential roles of ROS generation and XIAP reduction in VCA-1-induced apoptosis in cancer cells. VCA-1 may be a novel cancer therapeutic agent, especially in p53-mutant human cancers.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/9918}
}